-
Whole-Blood Stimulation Reveals Metabolic Control
2026-09-19
Zhao and colleagues present a standardized ex vivo whole-blood protocol that links defined immune stimulation with targeted metabolic intervention and cytokine measurement. The approach preserves cellular and plasma context while improving comparability across donors, making it useful for immunometabolism, fatty acid oxidation pathway research, and translational assay development.
-
FAK Inhibitor 14: A Causal Assay Framework
2026-09-19
FAK Inhibitor 14 enables controlled interrogation of adhesion, migration, and EMT-linked signaling. This guide translates chronic cholesterol-stress findings into a rigorous assay strategy for cancer biology research and tumor metastasis research.
-
Mubritinib (TAK 165): Assay Design Guide
2026-09-18
This scenario-based guide explains how to select concentrations, manage solubility, interpret viability data, and compare vendors when using Mubritinib (TAK 165), SKU B1543. It connects complex I inhibition with practical AML, PEL, HER2, and assay-validation workflows while distinguishing product-supported evidence from laboratory recommendations.
-
Reactive Oxygen Species Assay Kit for FLASH-RT
2026-09-18
Use live-cell DCFH-DA fluorescence to connect treatment exposure with oxidative stress, apoptosis, and DNA-damage phenotypes. This workflow translates the BRD4-targeted FLASH-radiotherapy findings into practical controls, timing experiments, and troubleshooting decisions without treating ROS fluorescence as a standalone mechanism.
-
SP600125 JNK Inhibitor: Applied Workflows
2026-09-17
SP600125 offers a practical way to test JNK-dependent phosphorylation, cytokine release, and cell-death phenotypes across cellular and inflammatory models. This guide combines compound-handling guidance with assay controls and a phosphosite-aware strategy inspired by recent chemoproteomic research.
-
Mubritinib Sensitizes NSCLC to Cisplatin
2026-09-17
The reference study shows that Mubritinib, also known as TAK 165, can strengthen cisplatin activity in non-small cell lung cancer by disrupting mitochondrial function, increasing reactive oxygen species, and promoting apoptosis. Its screening-to-xenograft design provides a mechanistic rationale for combining mitochondrial stress with DNA-damaging chemotherapy, while also defining important limits for translating the findings beyond the tested models.
-
CX-5461 RNA Polymerase I Inhibitor Workflow
2026-09-16
CX-5461 is an RNA polymerase I inhibitor for connecting ribosome biogenesis stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This workflow emphasizes mechanism-linked assays, practical formulation controls, and combination studies relevant to solid tumor growth inhibition.
-
Crizotinib Hydrochloride in Gastric Assembloids
2026-09-15
Crizotinib hydrochloride provides a practical ALK, c-Met, and ROS1 pathway probe for patient-derived gastric cancer assembloids. Combining target-engagement measurements with matched tumor–stroma models can reveal response shifts that are invisible in organoid-only screens.
-
Latrunculin B for Actin Dynamics Workflows
2026-09-15
Latrunculin B offers a cell-permeable, short-duration way to test how actin filament assembly shapes morphology, trafficking, and entry phenotypes. Its serum-sensitive activity makes it especially useful for timed perturbations, matched vehicle controls, and mechanistic experiments where a negative result can be as informative as a positive one.
-
Wnt agonist 1: Assay Logic for Wnt–GPX4 Studies
2026-09-14
Wnt agonist 1, also known as BML-284, provides a controlled way to study canonical Wnt signaling and β-catenin–TCF transcription. This article develops an evidence-aware assay framework linking pathway activation with differentiation, metabolism, and chemoresistance without overstating what current data prove.
-
Mubritinib (TAK 165): Beyond HER2
2026-09-14
Mubritinib (TAK 165) is best understood not simply as a historical HER2 inhibitor, but as a mechanistically useful perturbation of mitochondrial complex I and oxidative phosphorylation. This thought-leadership analysis connects its activity in chemotherapy-resistant AML and KSHV-positive PEL with translational study design, formulation, pharmacology, and evidence discipline. It also explains why pH-mediated absorption research provides a valuable framework without justifying direct extrapolation to Mubritinib.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-13
A 2026 Advanced Science study uses single-cell profiling to identify SLC2A5-mediated fructose metabolism as a metabolic vulnerability in primary central nervous system lymphoma. Its findings connect glucose-poor, hypoxic tumor microenvironments with lymphoma-cell adaptation, macrophage support, and T-cell dysfunction, while functional perturbations provide a rationale for spatial and mechanistic validation.
-
Alpha-Ketoglutarate Workflows for Metabolic Research
2026-09-12
Use alpha-ketoglutarate as a controlled metabolic perturbation, an enzyme substrate, and a mechanistic probe for tumor–immune interactions. This workflow translates PDHA1 succinylation findings into practical metabolite, signaling, and macrophage antigen-presentation assays while separating exploratory conditions from established evidence.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-12
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical tumor suppressor replacement in bladder cancer. Its preclinical results link bladder-restricted expression with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced orthotopic tumor growth, while also defining important questions for formulation and translational validation.
-
Carbapenemase Gene Transmission in Enterobacter cloacae
2026-09-11
Chen et al. combined gene localization, susceptibility testing, plasmid conjugation, mobile-element analysis, and ERIC-PCR to characterize carbapenem-resistant Enterobacter cloacae across eight Guangdong teaching hospitals. The study identifies plasmid-associated blaNDM-1 as a major transferable resistance determinant and shows how horizontal gene transfer and clonal dissemination can coexist in hospital surveillance.